Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 409 participants.

Also called NCT01953328

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 409 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01953328
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01953328. Randomized; triple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2015-12-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
Acronym
AMG145
Condition
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Intervention (Drug)
Atorvastatin
Intervention (Biological)
Evolocumab
Intervention (Other)
Placebo to Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01953328
Content hash
34e8ccab6fa0f5a8fd60b0f4ca976d2c97a2c720f4946f925f0185f248c769ee